SCHEMBL6944134

SCHEMBL6944134

N#CCCn1c(CCCO)nc2ccccc21

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.62
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
SMN1; SMN2 Q16637 3/20 0.59
LMNA P02545 4/20 0.58
TSHR P16473 3/20 0.57
PKM P14618 1/20 0.57
POLB P06746 2/20 0.57
TP53 P04637 2/20 0.57
HTT P42858 1/20 0.57
NPSR1 Q6W5P4 1/20 0.54
TDP1 Q9NUW8 1/20 0.50
APEX1 P27695 1/20 0.50
KDM4E B2RXH2 2/20 0.48
MAPK1 P28482 1/20 0.48
CASP1 P29466 1/20 0.48
CASP7 P55210 1/20 0.48
HSD17B10 Q99714 1/20 0.48
HPGD P15428 1/20 0.47
MAPT P10636 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8364740 0.86 LMNA (0.64) ALDH1A1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL20665112 0.83 LMNA (0.61) ALDH1A1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL6488431 0.81 SMN1; SMN2 (0.61) ALDH1A1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL7013605 0.81 LMNA (0.56) ALDH1A1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL7006301 0.81 LMNA (0.59) ALDH1A1KMT2ASMN1; SMN2LMNATSHR
SCHEMBL24943126 0.80 LMNA (0.64) ALDH1A1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL8365517 0.80 LMNA (0.68) ALDH1A1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL7133651 0.80 LMNA (0.58) ALDH1A1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL15294614 0.78 SMN1; SMN2 (0.86) ALDH1A1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL11743461 0.77 KDM4E (0.58) ALDH1A1MEN1KMT2ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1235798-A4 1,4 SUBSTITUTED PIPERIDINYL NMDA/NR2B ANTAGONISTS MERCK & CO INC (US) 2003-04-23 EP disclosed
EP-1244450-A4 8-AZA-BICYCLO[3.2.1]OCTANE NMDA/NR2B ANTAGONISTS MERCK & CO INC (US) 2003-03-19 EP disclosed
US-20030018038-A1 1,4 substituted piperidinyl NMDA/NR2B antagonists MERCK & CO., INC. 2003-01-23 US disclosed
US-6476041-B1 1,4 substituted piperidinyl NMDA/NR2B antagonists MERCK & CO., INC. 2002-11-05 US disclosed
EP-1244450-A1 8-AZA-BICYCLO[3.2.1]OCTANE NMDA/NR2B ANTAGONISTS Merck & Co., Inc. (US) 2002-10-02 EP disclosed
EP-1235798-A1 1,4 SUBSTITUTED PIPERIDINYL NMDA/NR2B ANTAGONISTS Merck & Co., Inc. (US) 2002-09-04 EP disclosed
US-6432976-B1 ANALGESICS; SIDE EFFECT REDUCTION MERCK & CO., INC. 2002-08-13 US disclosed
WO-2001032615-A1 1,4 SUBSTITUTED PIPERIDINYL NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2001-05-10 WO disclosed
WO-2001032179-A1 8-AZA-BICYCLO[3.2.1]OCTANE NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2001-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018038-A1 1,4 substituted piperidinyl NMDA/NR2B antagonists GRIN1, GRIN2A, GRIN2B ALDH1A1 2346/4885MEN1 4657/4885KMT2A 705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.